SCHEMBL16438699

SCHEMBL16438699

CC(C)(C)OC(=O)N1CCC2(CC1)OCCNC2=O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ CCR5 P51681 2/20 0.40
▸ RECQL P46063 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ DDB1 Q16531 1/20 0.39
▸ CRBN Q96SW2 1/20 0.39
▸ TSHR P16473 2/20 0.38
▸ ALOX15 P16050 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ OPRD1 P41143 1/20 0.38
▸ OPRK1 P41145 1/20 0.38
▸ GPR119 Q8TDV5 1/20 0.36
▸ AVPR1A P37288 1/20 0.36
▸ CCNC P24863 1/20 0.36
▸ CDK8 P49336 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17725809 0.95 USP2 (0.43) USP2SMN1; SMN2CCR5RECQLKDM4E
SCHEMBL17760306 0.81 USP2 (0.46) USP2SMN1; SMN2CCR5RECQLKDM4E
SCHEMBL16914415 0.80 USP2 (0.50) USP2SMN1; SMN2RECQLKDM4EMAPT
SCHEMBL31580621 0.79 GAA (0.31) CRBN
SCHEMBL2338577 0.78 CCNC (0.49) USP2SMN1; SMN2CCR5KDM4EMAPT
SCHEMBL17760295 0.77 USP2 (0.41) USP2SMN1; SMN2CCR5RECQLKDM4E
SCHEMBL17725623 0.77 USP2 (0.41) USP2SMN1; SMN2CCR5RECQLKDM4E
SCHEMBL19379559 0.77 USP2 (0.41) USP2SMN1; SMN2CCR5RECQLKDM4E
SCHEMBL17310499 0.77 USP2 (0.43) USP2SMN1; SMN2CCR5KDM4EMAPT
SCHEMBL22799174 0.76 USP2 (0.47) USP2SMN1; SMN2RECQLDDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220204507-A1 NITROGEN-CONTAINING SPIRO DERIVATIVE AS RET INHIBITOR GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) 2022-06-30 — — US disclosed
WO-2020200314-A1 NITROGEN-CONTAINING SPIRO DERIVATIVE AS RET INHIBITOR 南京明德新药研发有限公司 2020-10-08 — — WO disclosed
EP-3250204-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME (US) 2019-10-30 — — EP disclosed
EP-3250204-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME (US) 2019-10-30 — — EP disclosed
EP-3212618-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME (US) 2019-07-10 — — EP disclosed
EP-3212618-B1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME (US) 2019-07-10 — — EP disclosed
EP-3027625-B1 SPIRO-FUSED DERIVATIVES OF PIPERIDINE USEFUL FOR THE TREATMENT OF INTER ALIA HYPERTENSION AND ACUTE OR CHRONIC HEART FAILURE MERCK SHARP & DOHME (US) 2018-05-30 — — EP disclosed
EP-3027625-B1 SPIRO-FUSED DERIVATIVES OF PIPERIDINE USEFUL FOR THE TREATMENT OF INTER ALIA HYPERTENSION AND ACUTE OR CHRONIC HEART FAILURE MERCK SHARP & DOHME (US) 2018-05-30 — — EP disclosed
US-20180009807-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME LLC 2018-01-11 — — US disclosed
US-20180009807-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME LLC 2018-01-11 — — US disclosed
WO-2016122994-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2016-08-04 — — WO disclosed
WO-2016122994-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2016-08-04 — — WO disclosed
US-20160207922-A1 Inhibitors of the Renal Outer Medullary Potassium Channel MERCK SHARP & DOHME CORP. (US) 2016-07-21 — — US disclosed
US-20160207922-A1 Inhibitors of the Renal Outer Medullary Potassium Channel MERCK SHARP & DOHME CORP. (US) 2016-07-21 — — US disclosed
US-20160207922-A1 Inhibitors of the Renal Outer Medullary Potassium Channel MERCK SHARP & DOHME CORP. (US) 2016-07-21 — — US disclosed
WO-2016069426-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2016-05-06 — — WO disclosed
WO-2016065582-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2016-05-06 — — WO disclosed
WO-2016065602-A1 INHIBITORS OF RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2016-05-06 — — WO disclosed
WO-2016069430-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP. (US) 2016-05-06 — — WO disclosed
WO-2015017305-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL MERCK SHARP & DOHME CORP (US) 2015-02-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160207922-A1 Inhibitors of the Renal Outer Medullary Potassium Channel KCNJ11, KCNJ1, KCNJ2 USP2 4805/4885SMN1; SMN2 1659/4885CCR5 2649/4885
US-20180009807-A1 INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL KCNJ11, KCNJ1, KCNJ2 USP2 4810/4885SMN1; SMN2 1726/4885CCR5 2585/4885
US-20220204507-A1 NITROGEN-CONTAINING SPIRO DERIVATIVE AS RET INHIBITOR RET, NPR1, NEK2 USP2 4106/4885SMN1; SMN2 1679/4885CCR5 1964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback